secwatch.observer — SEC 8-K summary
======================================

Issuer:     Quince Therapeutics, Inc. (QNCX)
CIK:        0001662774
Form:       8-K
Filed at:   2023-08-10T23:59:59+00:00
Accession:  0001193125-23-209172
Event type: leadership
Sentiment:  negative
Materiality: 0.55
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Quince Therapeutics CMO Karen Smith to depart effective Sept 1, 2023
--------------------------------------------------------------------

- Chief Medical Officer Karen Smith, M.D., Ph.D. will depart on September 1, 2023.
- Separation agreement includes 12 months base salary severance plus prorated 2023 bonus and health benefits lump sum.
- Outstanding equity awards subject to 50% accelerated vesting; additional benefits if change in control occurs within 3 months after departure.
- Dr. Smith will continue as employee until the departure date under transition and separation agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1662774/000119312523209172/0001193125-23-209172-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1662774/000119312523209172/d538151d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-209172

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer